The femoropopliteal (fempop) segment — running from the superficial femoral artery down through the popliteal artery behind the knee — is the single most commonly treated territory in peripheral arterial disease, and also one of the most technically demanding. No single device category reliably handles every fempop lesion, which is why interventionalists draw from a broader toolkit: plain angioplasty, drug-coated balloons, self-expanding stents, and atherectomy systems, often in combination.
Plain Balloon Angioplasty: The Baseline Option
Standard balloon angioplasty remains a foundational tool for the fempop segment, particularly in shorter, less complex lesions. Its appeal lies in simplicity and leaving no permanent implant, sometimes described as a "leave nothing behind" strategy. Its main limitation is a comparatively higher restenosis rate in many lesion types compared with more supported approaches, particularly in longer lesions or those with significant elastic recoil after dilation.
Drug-Coated Balloons: Adding Anti-Restenotic Therapy
Drug-coated balloons (DCBs) build on plain angioplasty by delivering an antiproliferative drug, typically paclitaxel, to the vessel wall during a timed inflation, aiming to reduce the intimal hyperplasia that drives restenosis without leaving a metal scaffold behind. DCBs are commonly used for de novo fempop lesions and for in-stent restenosis. Their principal limitation is that they provide no mechanical support, so significant dissection or recoil after predilation may still necessitate stenting despite the DCB treatment.
Self-Expanding Nitinol Stents: When Scaffolding Is Needed
When a vessel does not hold open adequately after balloon treatment, or when the lesion is long or heavily diseased, a self-expanding nitinol stent provides mechanical scaffolding engineered to tolerate the fempop segment's repetitive flexion and compression. This mechanical durability is precisely why nitinol became the standard material here, but stenting does introduce a permanent metal implant and its own restenosis considerations, including in-stent intimal hyperplasia over time.
Atherectomy: Preparing the Vessel Rather Than Treating It Alone
Atherectomy — rotational, directional, or orbital debulking of plaque — is generally used as a vessel-preparation step rather than a standalone treatment, particularly in heavily calcified fempop lesions where balloons alone may not achieve adequate luminal gain. By modifying calcium and plaque burden before balloon or DCB treatment, atherectomy is intended to improve the vessel's response to subsequent dilation, though it does not by itself address the biological process of restenosis.
How These Tools Combine in Practice
Rather than a single universal algorithm, fempop treatment strategy is built lesion by lesion. A short, non-calcified stenosis might be treated with angioplasty and a DCB alone. A heavily calcified, longer lesion might require atherectomy for vessel preparation, followed by DCB or stenting depending on how the vessel responds after debulking. A lesion with substantial recoil or flow-limiting dissection after DCB treatment may still need a stent placed as a bailout. This lesion-specific decision-making, rather than a fixed rule, is why fempop intervention is often described as requiring clinical judgment as much as technical skill.
INVAMED's Fempop-Relevant Devices
INVAMED's portfolio for femoropopliteal intervention includes the Extender Drug (Eluting) PTA Balloon Catheter, a paclitaxel-coated device for peripheral PTA with manufacturer-reported diameters of 1.5–12.0 mm and lengths of 20–220 mm, described on the Extender Drug PTA Balloon Catheter product page. The company's self-expanding Atlas Peripheral Stent System and TemREN rotational atherectomy system round out a toolkit spanning each of the strategies described above. Availability and specific indications for each device vary by country; refer to the Instructions for Use (IFU) and the broader peripheral arterial disease device category for further detail.
Why No Single Technology Wins Universally
Comparative studies of these approaches generally find that outcomes depend heavily on lesion length, calcification, and vessel diameter rather than one technology being superior across all fempop disease. A qualified physician weighs these lesion-specific factors, along with patient comorbidities and prior treatment history, when building an individualized treatment plan rather than defaulting to a single preferred device category.
How do doctors decide which combination of tools to use?
The decision is based on lesion length, calcification, reference vessel diameter, and how the vessel responds during the procedure itself, alongside the patient's overall clinical picture and treatment history. This is why the specific combination of tools used can differ meaningfully between two patients with seemingly similar symptoms.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.